The new EU Pharmaceutical Strategy has opened a window of opportunity “wide open” for the optimization of Europe’s regulatory environment, according to off-patent industry association Medicines for Europe.
Attendees to the association’s Regulatory Affairs and Pharmacovigilance virtual conference in late January heard that this opportunity went well beyond...




